{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:19:42Z","timestamp":1785809982047,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,23]]},"DOI":"10.7759\/cureus.62981","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T21:28:31Z","timestamp":1719178111000},"source":"Crossref","is-referenced-by-count":5,"title":["RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions"],"prefix":"10.7759","author":[{"given":"Prashil","family":"Dave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Kothawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakhyath","family":"Srikaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipsa","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o A","year":"2015","unstructured":"Casta\u00f1o A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015, 20:163-178. 10.1007\/s10741-014-9462-7","journal-title":"Heart Fail Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1242815","article-title":"Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy","volume":"14","author":"Poli L","year":"2023","unstructured":"Poli L, Labella B, Cotti Piccinelli S, et al.. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023, 14:1242815. 10.3389\/fneur.2023.1242815","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike H","year":"2002","unstructured":"Koike H, Misu K, Ikeda S, et al.. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002, 59:1771-1776. 10.1001\/archneur.59.11.1771","journal-title":"Arch Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima Y","year":"2015","unstructured":"Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015, 86:1036-1043. 10.1136\/jnnp-2014-308724","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu B","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020, 5:101. 10.1038\/s41392-020-0207-x","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri K","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, Bahal R. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020, 9:9. 10.3390\/jcm9062004","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115073","article-title":"RNAi therapies: expanding applications for extrahepatic diseases and overcoming delivery challenges","volume":"201","author":"Won Lee J","year":"2023","unstructured":"Won Lee J, Kyu Shim M, Kim H, Jang H, Lee Y, Hwa Kim S. RNAi therapies: expanding applications for extrahepatic diseases and overcoming delivery challenges. Adv Drug Deliv Rev. 2023, 201:115073. 10.1016\/j.addr.2023.115073","journal-title":"Adv Drug Deliv Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten RL","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019, 18:421-446. 10.1038\/s41573-019-0017-4","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo A","year":"2022","unstructured":"Aimo A, Castiglione V, Rapezzi C, et al.. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022, 19:655-667. 10.1038\/s41569-022-00683-z","journal-title":"Nat Rev Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082148","article-title":"Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges","volume":"11","author":"Tsch\u00f6pe C","year":"2022","unstructured":"Tsch\u00f6pe C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges. J Clin Med. 2022, 11:2148. 10.3390\/jcm11082148","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams D","year":"2021","unstructured":"Adams D, Polydefkis M, Gonz\u00e1lez-Duarte A, et al.. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021, 20:49-59. 10.1016\/S1474-4422(20)30368-9","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams D","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al.. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023, 30:1-9. 10.1080\/13506129.2022.2091985","journal-title":"Amyloid"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich M","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs. 2022, 36:549-571. 10.1007\/s40259-022-00549-3","journal-title":"BioDrugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho T","year":"2023","unstructured":"Coelho T, Marques W Jr, Dasgupta NR, et al.. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023, 330:1448-1458. 10.1001\/jama.2023.18688","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168875","article-title":"Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets","volume":"23","author":"Barresi V","year":"2022","unstructured":"Barresi V, Musmeci C, Rinaldi A, Condorelli DF. Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets. Int J Mol Sci. 2022, 23:8875. 10.3390\/ijms23168875","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire A","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998, 391:806-811. 10.1038\/35888","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2019-0321","article-title":"Perspectives, issues and solutions in RNAi therapy: the expected and the less expected","volume":"14","author":"Aigner A","year":"2019","unstructured":"Aigner A. Perspectives, issues and solutions in RNAi therapy: the expected and the less expected. Nanomedicine (Lond). 2019, 14:2777-2782. 10.2217\/nnm-2019-0321","journal-title":"Nanomedicine (Lond)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1069132","article-title":"RNA-dependent RNA polymerases, viruses, and RNA silencing","volume":"296","author":"Ahlquist P","year":"2002","unstructured":"Ahlquist P. RNA-dependent RNA polymerases, viruses, and RNA silencing. Science. 2002, 296:1270-1273. 10.1126\/science.1069132","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22380-3_2","article-title":"The microRNA machinery","volume":"887","author":"Roberts TC","year":"2015","unstructured":"Roberts TC. The microRNA machinery. Adv Exp Med Biol. 2015, 887:15-30. 10.1007\/978-3-319-22380-3_2","journal-title":"Adv Exp Med Biol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3298","article-title":"Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown","volume":"33","author":"Wittrup A","year":"2015","unstructured":"Wittrup A, Ai A, Liu X, et al.. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol. 2015, 33:870-6. 10.1038\/nbt.3298","journal-title":"Nat Biotechnol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams D","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019, 15:387-404. 10.1038\/s41582-019-0210-4","journal-title":"Nat Rev Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7010011","article-title":"Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights","volume":"7","author":"Koike H","year":"2019","unstructured":"Koike H, Katsuno M. Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines. 2019, 7:11. 10.3390\/biomedicines7010011","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04889-2","article-title":"Hereditary transthyretin amyloidosis overview","volume":"43","author":"Manganelli F","year":"2022","unstructured":"Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2022, 43:595-604. 10.1007\/s10072-020-04889-2","journal-title":"Neurol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416133","article-title":"A metabolic signature of hereditary transthyretin amyloidosis: a pilot study","volume":"23","author":"Luigetti M","year":"2022","unstructured":"Luigetti M, Guglielmino V, Romano A, et al.. A metabolic signature of hereditary transthyretin amyloidosis: a pilot study. Int J Mol Sci. 2022, 23:16133. 10.3390\/ijms232416133","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S361706","article-title":"Practical guidance for the use of patisiran in the management of polyneuropathy in hereditary transthyretin-mediated amyloidosis","volume":"19","author":"Dixon S","year":"2023","unstructured":"Dixon S, Kang X, Quan D. Practical guidance for the use of patisiran in the management of polyneuropathy in hereditary transthyretin-mediated amyloidosis. Ther Clin Risk Manag. 2023, 19:973-981. 10.2147\/TCRM.S361706","journal-title":"Ther Clin Risk Manag"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01633-z","article-title":"Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus","volume":"15","author":"Grandis M","year":"2020","unstructured":"Grandis M, Obici L, Luigetti M, et al.. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis. 2020, 15:348. 10.1186\/s13023-020-01633-z","journal-title":"Orphanet J Rare Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho T","year":"2013","unstructured":"Coelho T, Adams D, Silva A, et al.. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013, 369:819-829. 10.1056\/NEJMoa1208760","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: discovery, pharmacology and clinical development-An introductory review","volume":"180","author":"Ranasinghe P","year":"2023","unstructured":"Ranasinghe P, Addison ML, Dear JW, Webb DJ. Small interfering RNA: discovery, pharmacology and clinical development-An introductory review. Br J Pharmacol. 2023, 180:2697-2720. 10.1111\/bph.15972","journal-title":"Br J Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of Patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits I","year":"2020","unstructured":"Urits I, Swanson D, Swett MC, et al.. A review of Patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020, 9:301-315. 10.1007\/s40120-020-00208-1","journal-title":"Neurol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams D","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018, 379:11-21. 10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr OB","year":"2015","unstructured":"Suhr OB, Coelho T, Buades J, et al.. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015, 10:109. 10.1186\/s13023-015-0326-6","journal-title":"Orphanet J Rare Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam BA","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, et al.. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021, 109:372-382. 10.1002\/cpt.1974","journal-title":"Clin Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson MD","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al.. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018, 379:22-31. 10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2012.673140","article-title":"Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy","volume":"19 Suppl 1","author":"Ackermann EJ","year":"2012","unstructured":"Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012, 19 Suppl 1:43-44. 10.3109\/13506129.2012.673140","journal-title":"Amyloid"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides","volume":"23","author":"Ackermann EJ","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD, et al.. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid. 2016, 23:148-157. 10.1080\/13506129.2016.1191458","journal-title":"Amyloid"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14285","article-title":"Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial","volume":"27","author":"Brannagan TH","year":"2020","unstructured":"Brannagan TH, Wang AK, Coelho T, et al.. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol. 2020, 27:1374-1381. 10.1111\/ene.14285","journal-title":"Eur J Neurol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11276-8","article-title":"Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update","volume":"269","author":"Brannagan TH","year":"2022","unstructured":"Brannagan TH, Coelho T, Wang AK, et al.. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. J Neurol. 2022, 269:6416-6427. 10.1007\/s00415-022-11276-8","journal-title":"J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney NJ","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ, et al.. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 2021, 8:652-661. 10.1002\/ehf2.13154","journal-title":"ESC Heart Fail"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15468","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis","volume":"88","author":"Diep JK","year":"2022","unstructured":"Diep JK, Yu RZ, Viney NJ, et al.. Population pharmacokinetic\/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis. Br J Clin Pharmacol. 2022, 88:5389-5398. 10.1111\/bcp.15468","journal-title":"Br J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"7","author":"Masri A","year":"2023","unstructured":"Masri A, Maurer MS, Claggett BL, et al.. Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis. J Card Fail. 2023, 7:10.1016\/j.cardfail.2023.11.016","journal-title":"J Card Fail"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030512","article-title":"Use of technetium-99m-pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy","volume":"16","author":"Yu AL","year":"2024","unstructured":"Yu AL, Chen YC, Tsai CH, et al.. Use of technetium-99m-pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2024, 16:030512. 10.1161\/JAHA.123.030512","journal-title":"J Am Heart Assoc"},{"key":"ref42","unstructured":"Ionis Pharmaceuticals, Inc. A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM). (2024). https.\/\/clinicaltrials.gov\/study\/NCT04136171."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.21542\/gcsp.2023.4","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit S","year":"2023","unstructured":"Kotit S. Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy. Glob Cardiol Sci Pract. 2023, 2023:e202304. 10.21542\/gcsp.2023.4","journal-title":"Glob Cardiol Sci Pract"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore JD","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al.. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021, 385:493-502. 10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku402","article-title":"CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences","volume":"42","author":"Lin Y","year":"2014","unstructured":"Lin Y, Cradick TJ, Brown MT, et al.. CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 2014, 42:7473-7485. 10.1093\/nar\/gku402","journal-title":"Nucleic Acids Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid\u00a0cardiomyopathy","volume":"74","author":"Judge DP","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH, et al.. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid\u00a0cardiomyopathy. J Am Coll Cardiol. 2019, 74:285-295. 10.1016\/j.jacc.2019.03.012","journal-title":"J Am Coll Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore JD","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al.. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024, 390:132-142. 10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon A","year":"2021","unstructured":"Michalon A, Hagenbuch A, Huy C, et al.. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021, 12:3142. 10.1038\/s41467-021-23274-x","journal-title":"Nat Commun"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia P","year":"2023","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E, et al.. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med. 2023, 389:239-250. 10.1056\/NEJMoa2303765","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-022-10237-7","article-title":"Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis","volume":"27","author":"Morfino P","year":"2022","unstructured":"Morfino P, Aimo A, Panichella G, Rapezzi C, Emdin M. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Fail Rev. 2022, 27:2187-2200. 10.1007\/s10741-022-10237-7","journal-title":"Heart Fail Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/261263-rna-interference-therapeutics-for-hereditary-amyloidosis-a-narrative-review-of-clinical-trial-outcomes-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T21:28:37Z","timestamp":1719178117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/261263-rna-interference-therapeutics-for-hereditary-amyloidosis-a-narrative-review-of-clinical-trial-outcomes-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,23]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.62981","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,23]]}}}